Beam Therapeutics Inc: CEO director John M. Evans sold 50,000 shares

What happened

• John M. Evans, CEO and director, exercised options and sold shares. The filing shows exercises of 25,000 shares on Oct 15, 2026 (acquired at $1.03, $25,750) and 25,000 shares on Oct 16, 2026 (acquired at $1.03, $25,750), and open-market sales of 25,000 shares on Oct 15, 2026 (sold at a weighted average $23.57 for $589,150) and 25,000 shares on Oct 16, 2026 (sold at a weighted average $23.98 for $599,595). Total reported sale proceeds equal $1,188,745 and total reported exercise cost equals $51,500.
• The filing also lists two M-code entries for 25,000 shares each with a $0.00 price marked as disposed (derivative).

Key details

• Transaction dates and prices: Oct 15, 2026 — exercised 25,000 @ $1.03 (acquired) and sold 25,000 @ weighted avg $23.57 (range $23.23–$23.84 per footnote); Oct 16, 2026 — exercised 25,000 @ $1.03 (acquired) and sold 25,000 @ weighted avg $23.98 (range $23.66–$24.56 per footnote).
• Shares owned after the transaction: not provided in the filing excerpt.
• Relevant footnotes: the exercises and sales were executed pursuant to a Rule 10b5-1 trading plan adopted Jun 16, 2026 (F1); weighted-average sale prices and price ranges are shown in footnotes (F2, F3); the options were part of a grant made Jul 13, 2018 with standard vesting (F4).
• Filing date: Oct 16, 2026 (as filed with the SEC).

Why it may matter

• The filing shows exercised options with the acquired shares sold under a Rule 10b5-1 plan (shares were sold after exercise).
• The filing reports both the option exercise and the subsequent open-market sales; it does not by itself explain the mechanics beyond the footnotes.
• The filing does not show why the insider traded or why the company acted.